晚期非小细胞肺癌吉非替尼治疗性别与疗效相关性分析  

Efficacy of gefitinib on advanced non-small cell lung cancer patients with different sex

作　　者：杨钰贤[1] 丘希辉[1] 陈志明[1] 庄晓文[1] 张盛奇[1] 

机构地区：[1]汕头大学医学院附属肿瘤医院肿瘤内科,广东汕头515031

出　　处：《中华肿瘤防治杂志》2011年第16期1277-1279,共3页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:探讨吉非替尼对不同性别晚期非小细胞肺癌(NSCLC)患者的疗效和安全性。方法:选择化疗失败的晚期NSCLC患者74例,分为女性组(36例)和男性组(38例),应用吉非替尼进行单药治疗,口服剂量为250 mg/d。分析两组治疗疗效和安全性。结果:女性组和男性组的总有效率(47.2%vs 26.3%,P=0.062)以及中位无进展生存期(7.9个月vs 5.7个月,P=0.093)差异均无统计学意义;而其中女性腺癌患者的有效率(53.8%)与以及中位无进展生存期(10.1个月)明显优于男性鳞癌患者,差异均有统计学意义,P值均<0.05。两组的不良反应相似主要为皮疹和腹泻。结论:对于晚期NSCLC患者,在无检测表皮生长因子受体(EGFR)情况下,合理选择优势人群,应用分子靶向药物吉非替尼治疗,疗效较高,能有助于提高NSCLC临床个体化治疗水平。OBJECTIVE：To select dominant crowd in advanced non-small-cell lung cancer（NSCLC） by comparing the efficacy and safety of gefitinib on advanced NSCLC in different gender groups.METHODS： Seventy-four advanced NSCLC patients（36 female and 38 male） who failed in previous chemotherapy perorally received gefitinib 250 mg/d.The efficacy and safety of gefitinib on advanced NSCLC between the two groups was compared.RESULTS： Neither the overall response rate（47.2% vs 26.3%,P=0.062） nor the median progression free survival（7.9 months vs 5.7 months,P=0.093） between the female and male patients indicated any significant difference.However,the overall response rate（53.8%） as well as the median progression-free survival（10.1 months） were significantly higher in the female patients with adenocarcinoma than that in the male patients with squamous carcinoma（P0.05）.The main toxicities were skin rash and diarrhea which was similar in the two groups.CONCLUSION： If EGFR has not been detected yet,rational selection of dominant crowd and well-planned treatment with gefitinib will be rewarding to enhance individualized therapy in NSCLC.

关 键 词：吉非替尼 癌 非小细胞肺 女性 男性 疗效 

分 类 号：R734.2[医药卫生—肿瘤]